Literature DB >> 31054324

CRISPR-Cas9: A multifaceted therapeutic strategy for cancer treatment.

Itishree Kaushik1, Sharavan Ramachandran1, Sanjay K Srivastava2.   

Abstract

CRISPR-Cas9 is an RNA guided endonuclease that has revolutionized the ability to edit genome and introduce desired manipulations in the target genomic sequence. It is a flexible methodology and is capable of targeting multiple loci simultaneously. Owing to the fact that cancer is an amalgamation of several genetic mutations, application of CRISPR-Cas9 technology is considered as a novel strategy to combat cancer. Genetic and epigenetic modulations in cancer leads to development of resistance to conventional therapy options. Given the abundance of transcriptomic and genomic alterations in cancer, developing a strategy to decipher these alterations is critical. CRISPR-Cas9 system has proven to be a promising tool in generating cellular and animal models to mimic the mutations and understand their role in tumorigenesis. CRISPR-Cas9 is an upheaval in the field of cancer immunotherapy. Furthermore, CRISPR-Cas9 plays an important role in the development of whole genome libraries for cancer patients. This approach will help understand the diversity in genome variation among the patients and also, will provide multiple variables to scientists to investigate and improvise cancer therapy. This review will focus on the discovery of CRISPR-Cas9 system, mechanisms behind CRISPR technique and its current status as a potential tool for investigating the genomic mutations associated with all cancer types.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  CRISPR-Cas9; Cancer; Genome editing

Mesh:

Year:  2019        PMID: 31054324      PMCID: PMC6829064          DOI: 10.1016/j.semcdb.2019.04.018

Source DB:  PubMed          Journal:  Semin Cell Dev Biol        ISSN: 1084-9521            Impact factor:   7.727


  106 in total

Review 1.  The discovery and development of the CRISPR system in applications in genome manipulation.

Authors:  Veronica Lau; James R Davie
Journal:  Biochem Cell Biol       Date:  2016-10-28       Impact factor: 3.626

Review 2.  CRISPR/Cas9 for genome editing: progress, implications and challenges.

Authors:  Feng Zhang; Yan Wen; Xiong Guo
Journal:  Hum Mol Genet       Date:  2014-03-20       Impact factor: 6.150

3.  Novel fusion transcripts associate with progressive prostate cancer.

Authors:  Yan P Yu; Ying Ding; Zhanghui Chen; Silvia Liu; Amantha Michalopoulos; Rui Chen; Zulfiqar G Gulzar; Bing Yang; Kathleen M Cieply; Alyssa Luvison; Bao-Guo Ren; James D Brooks; David Jarrard; Joel B Nelson; George K Michalopoulos; George C Tseng; Jian-Hua Luo
Journal:  Am J Pathol       Date:  2014-10       Impact factor: 4.307

4.  An inducible lentiviral guide RNA platform enables the identification of tumor-essential genes and tumor-promoting mutations in vivo.

Authors:  Brandon J Aubrey; Gemma L Kelly; Andrew J Kueh; Margs S Brennan; Liam O'Connor; Liz Milla; Stephen Wilcox; Lin Tai; Andreas Strasser; Marco J Herold
Journal:  Cell Rep       Date:  2015-02-26       Impact factor: 9.423

Review 5.  History of CRISPR-Cas from Encounter with a Mysterious Repeated Sequence to Genome Editing Technology.

Authors:  Yoshizumi Ishino; Mart Krupovic; Patrick Forterre
Journal:  J Bacteriol       Date:  2018-03-12       Impact factor: 3.490

6.  Rapid modelling of cooperating genetic events in cancer through somatic genome editing.

Authors:  Francisco J Sánchez-Rivera; Thales Papagiannakopoulos; Rodrigo Romero; Tuomas Tammela; Matthew R Bauer; Arjun Bhutkar; Nikhil S Joshi; Lakshmipriya Subbaraj; Roderick T Bronson; Wen Xue; Tyler Jacks
Journal:  Nature       Date:  2014-10-22       Impact factor: 49.962

7.  Engineered Cpf1 variants with altered PAM specificities.

Authors:  Linyi Gao; David B T Cox; Winston X Yan; John C Manteiga; Martin W Schneider; Takashi Yamano; Hiroshi Nishimasu; Osamu Nureki; Nicola Crosetto; Feng Zhang
Journal:  Nat Biotechnol       Date:  2017-06-05       Impact factor: 54.908

Review 8.  Unleashing the Therapeutic Potential of CAR-T Cell Therapy Using Gene-Editing Technologies.

Authors:  In-Young Jung; Jungmin Lee
Journal:  Mol Cells       Date:  2018-08-14       Impact factor: 5.034

9.  The Potential of CRISPR/Cas9 Gene Editing as a Treatment Strategy for Alzheimer's Disease.

Authors:  Troy T Rohn; Nayoung Kim; Noail F Isho; Jacob M Mack
Journal:  J Alzheimers Dis Parkinsonism       Date:  2018-05-31

10.  Efficient genome editing in zebrafish using a CRISPR-Cas system.

Authors:  Woong Y Hwang; Yanfang Fu; Deepak Reyon; Morgan L Maeder; Shengdar Q Tsai; Jeffry D Sander; Randall T Peterson; J-R Joanna Yeh; J Keith Joung
Journal:  Nat Biotechnol       Date:  2013-01-29       Impact factor: 54.908

View more
  3 in total

Review 1.  MicroRNAs and Epigenetics Strategies to Reverse Breast Cancer.

Authors:  Mohammad Mijanur Rahman; Andrew C Brane; Trygve O Tollefsbol
Journal:  Cells       Date:  2019-10-08       Impact factor: 6.600

2.  Novel lncRNA UPLA1 mediates tumorigenesis and prognosis in lung adenocarcinoma.

Authors:  Xiaoyang Han; Hua Jiang; Jianni Qi; Jiamei Li; Jinghan Yang; Yingying Tian; Wei Li; Qi Jing; Chuanxi Wang
Journal:  Cell Death Dis       Date:  2020-11-21       Impact factor: 8.469

Review 3.  A review of COVID-19: Treatment strategies and CRISPR/Cas9 gene editing technology approaches to the coronavirus disease.

Authors:  Muhammad Farhat Ullah; Yasir Ali; Muhammad Ramzan Khan; Inam Ullah Khan; Bing Yan; M Ijaz Khan; M Y Malik
Journal:  Saudi J Biol Sci       Date:  2021-10-13       Impact factor: 4.219

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.